Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein Occlusion in China

• Sponsor: Allergan (Industry)
• Overall Status: Completed
• CT.gov ID: NCT03908307
• Collaborator: (none)
• Enrollment: 150
• Locations: 9
• Arm: 1
• Actual Duration (Months): 26.1
• Patients Per Site: 16.7
• Patients Per Site Per Month: 0.6

Study Details

Study Description

Brief Summary

This study will take place in China to evaluate the safety and efficacy of OZURDEX implant 700 μg in the treatment of macular edema due to retinal vein occlusion (RVO) in patients who have never received treatment for RVO.

Condition or Disease	Intervention/Treatment	Phase
Macular Edema; Retinal Vein Occlusion	Drug: OZURDEX	Phase 4

Study Design

• Study Type: Interventional
• Actual Enrollment: 150 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A 12-month, Open-label, Multicenter, Phase 4 Study to Evaluate the Efficacy and Safety of OZURDEX® Implant 700 µg (Dexamethasone) on Patients With Macular Edema Secondary to Retinal Vein Occlusion in China (YANGTZE Study)
• Actual Study Start Date: Jul 25, 2019
• Actual Primary Completion Date: Sep 26, 2021
• Actual Study Completion Date: Sep 26, 2021

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Study Eye OZURDEX implant 700 μg	Drug: OZURDEX; Implant 700 μg

Outcome Measures

Primary Outcome Measures

1. Mean change in visual acuity from Baseline [At Month 6]

   Determined by best corrected visual acuity (BCVA)

2. Proportion of patients with a BCVA improvement of 15 letters or more compared to Baseline [At Month 6]

   Measured using the ETDRS visual acuity protocol

3. BCVA average change from Baseline in area under the curve (AUC) analysis [At Month 6]

Secondary Outcome Measures

1. Mean change from Baseline in BCVA [After first follow-up visit, at each injection, and at Month 12]

2. Mean change from Baseline in Central Retinal Thickness (CRT) [At Months 6 and 12]

3. Mean change from Baseline in the National Eye Institute (NEI) Visual Function Questionnaire (VFQ)-25 [At Months 6 and 12]

   25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better functioning. Original numeric values from the survey will be recoded with the worst and best possible scores set at 0 and 100 points, respectively. In this format, scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score.

4. Mean number of OZURDEX injections [During the 12-month study]

5. Mean retreatment interval in months [During the 12-month study]

6. Proportion of patients with 2nd injection [During the 12-month study]

7. Proportion of patients with 3rd injection [During the 12-month study]

8. Time to 2nd injection [During the 12-month study]

9. Time to 3rd injection [During the 12-month study]

10. Correlation between the change of BCVA and extent of leak by fluorescein angiography (FA) [At Month 6]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

Inclusion Criteria:

• Patient diagnosed with macular edema due to RVO (either BRVO or CRVO, non-ischemic)

• Retinal thickness ≥ 300 μm by SD-OCT in the central 1 mm macular subfield of the study eye at the Screening visit

• BCVA score of 19 to 73 letters (approximately 20/400 to 20/40 Snellen equivalent) in the study eye measured by ETDRS method at Screening

• < 3 months of macular edema duration

• Treatment-naive patients (ie, have not previously received any treatment for macular edema secondary to RVO)

Exclusion Criteria:

• Uncontrolled systemic disease

• Presence of/history of any ocular condition other than macular edema that affects visual acuity (eg, cataract, severe macular ischemia, foveal atrophy, age-related macular degeneration, uveitis or other ocular inflammatory disease, neovascular glaucoma, Irvine-Gass syndrome, prior macular detachment)

• Any of the following ≤ 3 months before study entry or anticipated need within the coming 3 months:

• Intraocular surgery

• Laser photocoagulation

• Intraocular injection

• Periocular steroid injection

• Vitrectomized eye

• Aphakic eyes with ruptured posterior lens capsule or presence of an ACIOL, iris or transscleral fixated intraocular lens

• History of marked IOP elevation in response to steroid treatment that (a) required IOP-lowering treatment, (b) resulted in a >10 mm Hg increase in IOP from predose, or (c) resulted in IOP >25 mm Hg

• History of glaucoma or ocular hypertension (IOP > 21 mm Hg), or optic nerve head change consistent with glaucoma damage, and/or glaucomatous visual field loss in the study eye (patients with a history of previous angle closure that has been successfully treated with either a laser or surgical peripheral iridotomy [PI] are allowed as long as the visual fields have been stable for > 1 year prior to study entry and the patient has been and can be safely dilated).

• Any active ocular infection (i.e., bacterial, viral, parasitic, or fungal) in either eye at the Screening visit

• Female patients who are pregnant, nursing, or planning a pregnancy, or who are of childbearing potential and not using a reliable means of contraception

• Any condition that may interfere or preclude participation in the study

• Use of systemic steroids (e.g., oral, intravenous, intramuscular, epidural, rectal, or extensive dermal) within 1 month prior to Baseline or anticipated use at any time during the study (inhaled, intranasal, and intra-articular/intrabursal corticosteroids are allowed)

• Use of immunosuppressants, immunomodulators, antimetabolites, and/or alkylating agents within 3 months prior to Baseline or anticipated use at any time during the study

• Use of warfarin or heparin within 2 weeks prior to Baseline or anticipated use within the study period

• Known allergy, hypersensitivity or contraindication to the study medication, its components, fluorescein or povidone iodine

• Current enrollment in another drug or device study within 30 days prior to Baseline

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Peking Union Medical College Hospital /ID# 233616	Beijing	Beijing	China	100730
2	Beijing Tongren Hospital, CMU /ID# 233608	Beijing		China	100730
3	The First Xiangya Hospital of Central South University /ID# 233627	Changsha Hunan		China	410008
4	The First Affiliated Hospital of Dalian Medical University /ID# 233688	Dalian		China	116011
5	Qilu Hospital of Shandong University /ID# 233605	Jinan		China	250012
6	The Eye and ENT Hospital Affiliated of Fudan Univesity /ID# 233666	Shanghai		China	200031
7	Shanghai General Hospital /ID# 233579	Shanghai		China	200080
8	Joint Shantou International Eye Center of Shantou University and The Chinese Uni /ID# 233580	Shantou		China	515041
9	Tianjin Eye Hospital /ID# 233581	Tianjin		China	300020

Sponsors and Collaborators

• Allergan

Investigators

• Study Director: ALLERGAN INC., Allergan

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Allergan
• ClinicalTrials.gov Identifier: NCT03908307
• Other Study ID Numbers: CMO-MA-EYE-0575
• First Posted: Apr 9, 2019
• Last Update Posted: Feb 28, 2022
• Last Verified: Feb 1, 2022

• Individual Participant Data (IPD) Sharing Statement: Yes
• Plan to Share IPD: Yes
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No
• Additional relevant MeSH terms: Macular Edema; Retinal Vein Occlusion; Edema; Dexamethasone; Dexamethasone acetate; BB 1101

Study Results

No Results Posted as of Feb 28, 2022